

=> d ibib abs hitrn l22 1-2

L22 ANSWER 1 OF 2 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:410373 HCPLUS
 DOCUMENT NUMBER: 137:137428
 TITLE: Synthesis and anti-Helicobacter pylori activity of
 pyloricidin derivatives: II. The combination of amino
 acid residues in the dipeptidic moiety and its effect
 on the anti-Helicobacter pylori activity
 AUTHOR(S): Hasuoka, Atsushi; Nishikimi, Yuji; Nakayama, Yutaka;
 Kamiyama, Keiji; Nakao, Masafumi; Miyagawa,
 Ken-Ichiro; Nishimura, Osamu; Fujino, Masahiko
 CORPORATE SOURCE: Medicinal Chemistry Research Laboratories I,
 Pharmaceutical Research Division, Takeda Chemical
 Industries, Ltd., Osaka, 532-8686, Japan
 SOURCE: Journal of Antibiotics (2002), 55(5), 499-507
 CODEN: JANTAJ; ISSN: 0021-8820
 PUBLISHER: Japan Antibiotics Research Association
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The novel natural antibiotics pyloricidin A, B and C, consisting of a
 common (2S,3R,4R,5S)-5-amino-2,3,4,6-tetrahydroxyhexanoyl-.beta.-D-
 phenylalanine moiety and a terminal peptidic moiety (pyloricidin A:
 L-valine-L-valine-L-leucine; pyloricidin B: L-valine-L-leucine;
 pyloricidin C: L-leucine), exhibit potent and highly selective
 anti-Helicobacter pylori activity. In order to develop more potent
 compds. and to investigate structure activity relationships for the
 peptidic moiety with regard to the combination of amino acids, a series of
 derivs. with various dipeptidic moieties were prep'd. and evaluated for
 their anti-H. pylori activity. The combination of the two amino acids in
 the moiety was found to have a significant effect on the activity; the
 compd. with Nva-Abu showed excellent anti-H. pylori activity with an MIC
 value of 0.013 .mu.g/mL against H. pylori TN2. In addn., this compd. was
 found to show 60% clearance of H. pylori from infected Mongolian gerbils
 upon repetitive oral administration (10 mg/kg, b. i. d. for 7 days).

IT 282549-81-9P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (synthesis and anti-Helicobacter pylori activity of pyloricidin
 derivs.)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 2 OF 2 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:475680 HCPLUS
 DOCUMENT NUMBER: 133:105346
 TITLE: Preparation of polyol-amino acid compounds having
 activity against Helicobacter pylori
 INVENTOR(S): Kamiyama, Keiji; Nishikimi, Yuji; Hasuoka, Atsushi;
 Nakao, Masafumi; Miyagawa, Ken-ichiro; Akiyama, Yohko
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2000040599	A1	20000713	WO 2000-JP23	20000106
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
JP 2000256395	A2	20000919	JP 2000-5735	20000106
EP 1140979	A1	20011010	EP 2000-900126	20000106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: JP 1999-1898 A 19990107
WO 2000-JP23 W 20000106
OTHER SOURCE(S): MARPAT 133:105346

OTHER SOURCE(S): MARPAT 133:105346



AB Title compds. I (X = L-serine, L-asparagine, or (S)-2-aminobutyric acid residue; Y is .alpha.-L-amino acid residue) or their salts or prodrugs having activity against Helicobacter bacteria were prepd. Thus, (S)-3-[[2S,3R,4R,5S)-5-[(L-norvalyl-(S)-2-aminobutyryl)amino]-2,3,4,6-tetrahydroxyhexanoyl]amino]-3-phenylpropionic acid, prepd. from a leucine-polyol isolated from *Bacillus* sp. HC-72, showed min. inhibitory concn. 0.025 mg/mL against *Helicobacter pylori*. Pharmaceutical formulations the above product are given.

IT 282549-81-9P

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT.

Meller 09/857, 887

28/04/2003

=> d his 119-123

(FILE 'REGISTRY' ENTERED AT 17:54:08 ON 28 APR 2003)

L19 15 S C24H38N4O9/MF *mol. form.*

L20 8 S L19 AND NR=1 *no. of rings = 1*

L21 1 S 282549-81-9/RN - *see displayed compd, next page*

FILE 'HCAPLUS' ENTERED AT 18:01:44 ON 28 APR 2003

L22 2 S L21 *2 cuts from CA Plus - attached*

FILE 'CAOLD' ENTERED AT 18:02:24 ON 28 APR 2003


L23 0 S L22 *2 cuts from CA Old*

~~FILE 'HCAPLUS' ENTERED AT 18:02:44 ON 28 APR 2003~~

=> d 121

L21 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
 RN 282549-81-9 REGISTRY
 CN .beta.-Alanine, L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-
 galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H38 N4 O9
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

Inventor Search


Meller 09/857,887

28/04/2003

=> d ibib abs hitstr 1-1

L17 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:475680 HCPLUS
 DOCUMENT NUMBER: 133:105346
 TITLE: Preparation of polyol-amino acid compounds having activity against Helicobacter pylori
 INVENTOR(S): Kamiyama, Keiji; Nishikimi, Yuji;
 Hasuoka, Atsushi; Nakao, Masafumi;
 Miyagawa, Ken-ichiro; Akiyama, Yohko
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040599	A1	20000713	WO 2000-JP23	20000106
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2000256395	A2	20000919	JP 2000-5735	20000106
EP 1140979	A1	20011010	EP 2000-900126	20000106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			JP 1999-1898	A 19990107
			WO 2000-JP23	W 20000106
OTHER SOURCE(S): GI		MARPAT 133:105346		



AB Title compds. I (X = L-serine, L-asparagine, or (S)-2-aminobutyric acid residue; Y is .alpha.-L-amino acid residue) or their salts or prodrugs having activity against Helicobacter bacteria were prep'd. Thus, (S)-3-[(2S,3R,4R,5S)-5-[(L-norvalyl-(S)-2-aminobutyryl)amino]-2,3,4,6-tetrahydroxyhexanoyl]amino]-3-phenylpropionic acid, prep'd. from a leucine-polyol isolated from *Bacillus* sp. HC-72, showed min. inhibitory concn. 0.025 mg/mL against *Helicobacter pylori*. Pharmaceutical formulations the above product are given.

IT 282549-81-9P 282549-83-1P


RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 282549-81-9 HCPLUS

CN .beta.-Alanine, L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-83-1 HCPLUS

CN .beta.-Alanine, L-isoleucyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 282549-69-3P 282549-71-7P 282549-73-9P

282549-75-1P 282549-77-3P 282549-79-5P

282549-85-3P 282549-87-5P 282549-89-7P

282549-91-1P 282549-93-3P 282549-95-5P

282549-98-8P 282550-00-9P 282550-02-1P

282550-04-3P 282550-06-5P 282550-09-8P


282550-21-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 282549-69-3 HCPLUS

CN .beta.-Alanine, L-norvalyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-71-7 HCPLUS

CN .beta.-Alanine, L-isoleucyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-73-9 HCPLUS

CN .beta.-Alanine, L-methionyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-75-1 HCPLUS

CN .beta.-Alanine, L-norvalyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-77-3 HCPLUS

CN .beta.-Alanine, L-isoleucyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-79-5 HCPLUS

CN .beta.-Alanine, L-methionyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-85-3 HCPLUS

CN .beta.-Alanine, L-methionyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-87-5 HCAPLUS

CN .beta.-Alanine, L-asparaginyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-89-7 HCAPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-91-1 HCAPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-93-3 HCPLUS

CN .beta.-Alanine, L-asparaginyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-95-5 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-98-8 HCPLUS

CN .beta.-Alanine, L-asparaginyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-00-9 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-02-1 HCPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-04-3 HCPLUS

CN .beta.-Alanine, L-lysyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-06-5 HCPLUS

CN .beta.-Alanine, L-valyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-09-8 HCPLUS

CN .beta.-Alanine, L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-21-4 HCPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219823-29-7P


RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 219823-29-7 HCPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219823-30-0P


RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 219823-30-0 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219812-79-0P 219812-94-9P 219812-99-4P
 219813-00-0P 282549-80-8P 282549-82-0P


RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 219812-79-0 HCPLUS

CN Benzene propanoic acid, β -[(5-amino-5-deoxy-L-galactonoyl)amino]-, (β .S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219812-94-9 HCPLUS

CN β -Alanine, N-(5-amino-5-deoxy-L-galactonoyl)-3-phenyl-, diphenylmethyl ester, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 219812-99-4 HCPLUS

CN β -Alanine, O-(1,1-dimethylethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-00-0 HCPLUS

CN .beta.-Alanine, O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-80-8 HCPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-82-0 HCPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 53064-79-2 77284-64-1

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of polyol-amino acid compds. having activity against
Helicobacter pylori)


RN 53064-79-2 HCPLUS

CN Propanoic acid, 2,2-dimethyl-, iodomethyl ester (9CI) (CA INDEX NAME)



RN 77284-64-1 HCPLUS

CN Butanoic acid, 2-[(1,1-dimethylethoxy)carbonyl]amino- (9CI) (CA INDEX NAME)




IT 90315-41-6P 219813-07-7P 282549-68-2P
 282549-70-6P 282549-72-8P 282549-74-0P
 282549-76-2P 282549-78-4P 282549-84-2P
 282549-86-4P 282549-88-6P 282549-90-0P
 282549-92-2P 282549-94-4P 282549-96-6P
 282549-97-7P 282549-99-9P 282550-01-0P
 282550-03-2P 282550-05-4P 282550-07-6P
 282550-08-7P 282550-10-1P 282550-11-2P
 282550-12-3P 282550-13-4P 282550-14-5P
 282550-15-6P 282550-16-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of polyol-amino acid compds. having activity against
Helicobacter pylori)

RN 90315-41-6 HCPLUS

CN L-Asparagine, N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-07-7 HCAPLUS

CN Benzene propanoic acid, β -[5-[(2S)-2-amino-1-oxobutyl]amino]-5-deoxy-L-galactonoyl]amino]-, monohydrochloride, $(\beta.S)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 282549-68-2 HCAPLUS

CN β -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-70-6 HCAPLUS

CN β -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-72-8 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-74-0 HCAPLUS

CN .beta.-Alanine, N-[(phenylmethoxy)carbonyl]-L-norvalyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-76-2 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-78-4 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-84-2 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-86-4 HCAPLUS

CN .beta.-Alanine, N2-[(1,1-dimethylethoxy)carbonyl]-L-asparaginyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-88-6 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-90-0 HCPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-S-methyl-L-cysteinyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-92-2 HCPLUS

CN .beta.-Alanine, N2-[(1,1-dimethylethoxy)carbonyl]-L-asparaginyl-N-(triphenylmethyl)-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-94-4 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-96-6 HCPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-S-methyl-L-cysteinyl-N-(triphenylmethyl)-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 282549-97-7 HCPLUS

CN .beta.-Alanine, N2-[(1,1-dimethylethoxy)carbonyl]-L-asparaginyl-(2S)-2-

aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-99-9 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-01-0 HCPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-S-methyl-L-cysteinyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 282550-03-2 HCPLUS

CN .beta.-Alanine, N6-[(1,1-dimethylethoxy)carbonyl]-N2-
 [(phenylmethoxy)carbonyl]-L-lysyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-
 galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OBu-t


RN 282550-05-4 HCPLUS
 CN .beta.-Alanine, N-[(phenylmethoxy)carbonyl]-L-valyl-(2S)-2-aminobutanoyl-5-
 amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 282550-07-6 HCPLUS
 CN .beta.-Alanine, N-[(phenylmethoxy)carbonyl]-L-norvalyl-(2S)-2-
 aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 282550-08-7 HCPLUS


CN .beta.-Alanine, N-[(phenylmethoxy)carbonyl]-L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 282550-10-1 HCPLUS

CN L-Asparagine, N-[(phenylmethoxy)carbonyl]-L-norvalyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-11-2 HCPLUS

CN L-Asparagine, N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-12-3 HCPLUS

CN Benzenepropanoic acid, .beta.-[[5-[(2S)-2-amino-1-oxobutyl]amino]-5-deoxy-L-galactonoyl]amino]-, diphenylmethyl ester, monohydrochloride, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 282550-13-4 HCPLUS

CN Benzenepropanoic acid, .beta.-[[5-[(2S)-2-amino-1,4-dioxo-4-[(triphenylmethyl)amino]butyl]amino]-5-deoxy-L-galactonoyl]amino]-, diphenylmethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-14-5 HCPLUS

CN L-Asparagine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-15-6 HCPLUS

CN Butanoic acid, 2-[[[(2S)-1-oxo-2-[(phenylmethoxy)carbonyl]amino]pentyl]ami-
no]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-16-7 HCPLUS

CN Benzenepropanoic acid, .beta.-[[5-[(2S)-2-[[[(9H-fluoren-9-
ylmethoxy)carbonyl]amino]-1,4-dioxo-4-[(triphenylmethyl)amino]butyl]amino]-
5-deoxy-L-galactonoyl]amino]-, diphenylmethyl ester, (.beta.S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

92662

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: *Mike Miller*Art Unit: *1654*

Phone Number 308-4230

Examiner #: *69404*Date: *4/28/02*Mail Box and Bldg/Rm Location: *CM-1 10A03*Serial Number: *09 857 887*

1/10/03

Results Format Preferred (circle): PAPER DISK E-MAILIf more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: *Polyl compounds their production & use*Inventors (please provide full names): *Keiji Kamiyama, Yuji Nishikimi, Atsushi Hisamatsu, Masafumi Nakao, Ken-ichiro Miyagawa, Yoko Akijama*Earliest Priority Filing Date: *1/7/99*

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please Search enclosed Structure.
 EX. 14 No good refs.


Mary Jane Ruhl
 Tech. Info. Specialist, STIC
 TC-1600
 CM-1, Room 6A-06
 Phone: 605-1155

STAFF USE ONLY


Searcher: _____
 Searcher Phone #: _____
 Searcher Location: _____
 Searcher Picked Up: *4/29/03*
 Completed: *4/29/03*
 Searcher Prep & Review Time: _____
 Actual Prep Time: _____
 Due Time: _____

Type of Search	Vendors and cost where applicable
NA Sequence (#)	STN _____
AA Sequence (#)	Dialog _____
Structure (#)	Questel/Orbit _____
Bibliographic	Dr. Link _____
Litigation	Lexis/Nexis _____
Fulltext	Sequence Systems _____
Patent Family	WWW/Internet _____
Other	Other (specify) _____


Compound of Example 13




Compound of Example 14




Compound of Example 15



Compound of Example 16



Compound of Example 17



Compound of Example 18

